Here is Why Growth Investors Should Buy HealthEquity (HQY) Now
Werte in diesem Artikel
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.Our proprietary system currently recommends HealthEquity (HQY) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).Here are three of the most important factors that make the stock of this provider of services for managing health care accounts a great growth pick right now.Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.While the historical EPS growth rate for HealthEquity is 1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 37.1% this year, crushing the industry average, which calls for EPS growth of 11.4%.Cash Flow GrowthWhile cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.Right now, year-over-year cash flow growth for HealthEquity is 27.9%, which is higher than many of its peers. In fact, the rate compares to the industry average of -13.8%.While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 30.3% over the past 3-5 years versus the industry average of 13.5%.Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.There have been upward revisions in current-year earnings estimates for HealthEquity. The Zacks Consensus Estimate for the current year has surged 1% over the past month.Bottom LineWhile the overall earnings estimate revisions have made HealthEquity a Zacks Rank #1 stock, it has earned itself a Growth Score of B based on a number of factors, including the ones discussed above.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.This combination positions HealthEquity well for outperformance, so growth investors may want to bet on it.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf HealthEquity
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf HealthEquity
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu HealthEquity Inc
Analysen zu HealthEquity Inc
Datum | Rating | Analyst | |
---|---|---|---|
07.02.2019 | HealthEquity Buy | Chardan Capital Markets | |
20.03.2018 | HealthEquity Buy | Chardan Capital Markets | |
06.12.2017 | HealthEquity Buy | Chardan Capital Markets | |
07.06.2017 | HealthEquity Buy | Chardan Capital Markets | |
31.03.2017 | HealthEquity Overweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
07.02.2019 | HealthEquity Buy | Chardan Capital Markets | |
20.03.2018 | HealthEquity Buy | Chardan Capital Markets | |
06.12.2017 | HealthEquity Buy | Chardan Capital Markets | |
07.06.2017 | HealthEquity Buy | Chardan Capital Markets | |
31.03.2017 | HealthEquity Overweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für HealthEquity Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen